GLP-1 drug plus standard chemo for first-line advanced cancers
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding a GLP-1 receptor agonist (a drug used for diabetes and weight loss) to standard chemotherapy can help people with advanced pancreatic, colorectal, or liver cancer. It is for people who have not yet started treatment for their metastatic disease and have a BMI of 25 or higher.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of pancreatic, colorectal, or liver cancer that has spread and cannot be removed with surgery.
- You have not yet received any chemotherapy or other systemic treatments for metastatic disease.
- You are willing to receive one of the standard chemotherapy regimens listed for your cancer type.
- Your body mass index (BMI) is 25 or higher.
- You have adequate organ function and are in generally good health (ECOG score 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
This trial tests a new combination of drugs for people with advanced liver cancer who have not had prior treatment. It compares the study drug QL1706 plus standard treatments to see if it can help shrink tumors or slow the disease.
This study tests whether adding L-glutamine (an amino acid supplement) to the usual chemotherapy for advanced pancreatic cancer can help the treatment work better. It aims to see if the combination is safe and effective for people who have not had chemo for their advanced disease.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This study tests a new drug (Retlirafusp alfa) combined with chemotherapy against a standard immunotherapy drug with chemotherapy for people with advanced stomach cancer that has spread to the liver. It aims to see if the new combination works better as a first-line treatment.
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.